1. [CASE 1 — QUESTION 1]
A 52-year-old man presents with progressive enlargement of his hands and feet, coarsening facial features, increased interdental spacing, and new-onset hypertension and glucose intolerance over the past 3 years. His primary care physician suspects acromegaly and refers him to endocrinology. Physical examination shows frontal bossing, macroglossia, and a prominent jaw. The endocrinologist plans confirmatory biochemical testing. Which of the following biochemical findings best confirms the diagnosis of acromegaly in this patient?
A) A single random serum GH (growth hormone) measurement above 1 ng/mL, which by itself definitively establishes the diagnosis without further testing
B) Failure of serum GH to suppress below 1 ng/mL (or below 0.4 ng/mL on an ultrasensitive assay) after a 75 g oral glucose tolerance test, combined with an elevated age- and sex-adjusted serum IGF-1 (insulin-like growth factor-1)
C) A suppressed serum IGF-1 (insulin-like growth factor-1) with a markedly elevated random GH, reflecting dissociation between the two markers in acromegaly
D) An exaggerated rise in serum GH following an oral glucose load, confirming autonomous somatotroph secretion
E) An elevated serum prolactin with a normal IGF-1 (insulin-like growth factor-1), which is the defining biochemical signature of acromegaly
ANSWER: B
Rationale:
The biochemical diagnosis of acromegaly rests on two findings together: failure of serum GH (growth hormone) to suppress below 1 ng/mL (or below 0.4 ng/mL on an ultrasensitive assay) after a 75 g oral glucose tolerance test, and an elevated age- and sex-adjusted serum IGF-1 (insulin-like growth factor-1). In healthy individuals, an oral glucose load suppresses GH; in acromegaly, autonomous somatotroph secretion (almost always from a pituitary adenoma) fails to suppress. Serum IGF-1, which reflects integrated 24-hour GH secretion, is elevated and serves as the confirmatory companion marker.
Option A: Option A is incorrect because a single random GH measurement is unreliable owing to the pulsatile nature of GH secretion; isolated values cannot establish the diagnosis, which requires demonstration of non-suppression on a glucose tolerance test plus an elevated IGF-1.
Option C: Option C is incorrect because in acromegaly IGF-1 is elevated, not suppressed; both GH (non-suppressible) and IGF-1 (elevated) move in the same direction, reflecting GH excess.
Option D: Option D is incorrect because the diagnostic criterion is failure of GH to suppress after glucose, not an exaggerated rise; a paradoxical rise can occur in some patients but the established criterion is non-suppression below the threshold.
Option E: Option E is incorrect because an elevated prolactin with a normal IGF-1 is not the signature of acromegaly; the defining feature is elevated IGF-1 with non-suppressible GH, and while some tumors co-secrete prolactin, that is not the diagnostic criterion.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. Biochemical testing confirms acromegaly: serum GH (growth hormone) fails to suppress on the oral glucose tolerance test and serum IGF-1 (insulin-like growth factor-1) is markedly elevated. Pituitary MRI (magnetic resonance imaging) reveals a 9 mm somatotroph macroadenoma confined to the sella without cavernous sinus invasion or chiasmal compression. The patient has no contraindication to surgery. What is the most appropriate first-line treatment?
A) Lifelong octreotide LAR (long-acting release) as definitive monotherapy, deferring any surgical intervention indefinitely
B) Pegvisomant monotherapy as the initial definitive treatment, reserving surgery only for drug failure
C) External-beam radiotherapy as the first-line modality, with medical therapy as a bridge until radiation takes effect
D) Transsphenoidal surgical resection of the adenoma, which is the first-line treatment for resectable somatotroph adenomas
E) Observation with serial imaging, deferring all treatment until the tumor demonstrates growth or causes mass effect
ANSWER: D
Rationale:
Transsphenoidal surgical resection is the first-line treatment for resectable somatotroph adenomas in acromegaly. This patient has a 9 mm macroadenoma confined to the sella without cavernous sinus invasion or chiasmal compression and no surgical contraindication, making him an excellent surgical candidate; resection offers the possibility of biochemical cure and immediate reduction of tumor mass. Medical therapy and radiotherapy are reserved for residual or recurrent disease, for poor surgical candidates, or for pre-surgical tumor control.
Option A: Option A is incorrect because somatostatin receptor analogs are used for residual or recurrent disease or when surgery is not feasible, not as the default definitive monotherapy in a resectable surgical candidate; deferring surgery indefinitely forgoes the chance of surgical cure.
Option B: Option B is incorrect because pegvisomant is a second-line agent for patients inadequately controlled by or intolerant of other therapy; it does not reduce tumor mass and is not first-line definitive treatment.
Option C: Option C is incorrect because radiotherapy is reserved for aggressive or drug-refractory tumors and has a delayed effect on GH/IGF-1 (often years); it is not the first-line modality for a resectable adenoma.
Option E: Option E is incorrect because active acromegaly causes progressive systemic complications (cardiovascular disease, glucose intolerance, sleep apnea), so observation alone is inappropriate when curative surgery is feasible.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. He undergoes transsphenoidal surgery. Three months postoperatively, repeat testing shows persistently elevated IGF-1 (insulin-like growth factor-1) and non-suppressible GH (growth hormone), indicating residual disease from incompletely resected tumor. His fasting glucose and HbA1c (hemoglobin A1c) are normal. The endocrinologist plans medical therapy for the residual disease. Which agent is the most appropriate first choice?
A) A first-generation somatostatin receptor analog (SSA) such as octreotide LAR (long-acting release) or lanreotide Autogel, which suppresses GH and IGF-1 by SSTR2 (somatostatin receptor subtype 2) agonism at the pituitary somatotroph and is the standard first-line medical therapy for residual acromegaly
B) Sermorelin, to stimulate the pituitary and restore normal feedback regulation of GH
C) Macimorelin, to provide both diagnostic confirmation and ongoing GH suppression
D) Tesamorelin, because its GHRH (growth hormone-releasing hormone) analog activity normalizes IGF-1 in residual acromegaly
E) High-dose somatropin, to overwhelm the residual tumor through negative feedback
ANSWER: A
Rationale:
First-generation somatostatin receptor analogs (SSAs) — octreotide LAR (long-acting release) and lanreotide Autogel — are the standard first-line medical therapy for residual acromegaly after incomplete surgical resection. They suppress GH and IGF-1 through SSTR2 (somatostatin receptor subtype 2) agonism at the pituitary somatotroph and can also provide tumor restraint. With normal glucose and HbA1c, this patient has no specific reason to start with a higher-hyperglycemia-risk agent.
Option B: Option B is incorrect because sermorelin is a GHRH analog that stimulates GH release; using it in acromegaly would worsen GH excess rather than control residual disease.
Option C: Option C is incorrect because macimorelin is a diagnostic ghrelin receptor agonist that stimulates GH and has no therapeutic role in suppressing GH in acromegaly.
Option D: Option D is incorrect because tesamorelin is a GHRH analog approved to stimulate GH for HIV-associated lipodystrophy; it raises rather than lowers GH/IGF-1 and is contraindicated in the context of GH excess.
Option E: Option E is incorrect because somatropin is recombinant GH used for replacement in deficiency; administering it in acromegaly would add to GH excess, not suppress the tumor.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. He is started on subcutaneous (SC) octreotide three times daily, tolerates it well, and is now being transitioned to the depot formulation octreotide LAR (long-acting release) given by intramuscular (IM) injection every 28 days for convenience. The endocrinologist must plan the transition to avoid loss of GH (growth hormone) control. Which approach is correct?
A) Stop SC octreotide the evening before the first octreotide LAR injection, because the depot reaches therapeutic levels within hours
B) Administer the first octreotide LAR dose at double strength and discontinue SC octreotide immediately, relying on an initial depot burst
C) Continue SC octreotide for approximately 14 days after the first octreotide LAR injection, because the poly(lactic-co-glycolic acid) (PLGA) microspheres do not release octreotide at therapeutic concentrations until roughly 2 weeks; SC bridging maintains GH suppression during this lag
D) Switch directly with no bridging, since octreotide LAR achieves steady therapeutic levels immediately, identical to lanreotide Autogel
E) Replace octreotide with oral octreotide tablets during the transition to provide immediate coverage
ANSWER: C
Rationale:
Octreotide LAR (long-acting release) consists of poly(lactic-co-glycolic acid) (PLGA) microspheres that do not release octreotide at therapeutic plasma concentrations until approximately 14 days after the first injection. If SC octreotide were stopped at the time of the first depot injection, the patient would have roughly 2 weeks of subtherapeutic levels and loss of GH control. The correct approach is to continue SC octreotide as bridging therapy for about 14 days after the first LAR dose, then discontinue it once the depot is therapeutic.
Option A: Option A is incorrect because octreotide LAR does not reach therapeutic levels within hours; stopping SC octreotide prematurely creates a 2-week gap in GH suppression.
Option B: Option B is incorrect because octreotide LAR microspheres do not produce a rapid therapeutic burst; the standard dose is used without doubling, and bridging remains necessary.
Option D: Option D is incorrect because immediate steady-state without a loading lag describes lanreotide Autogel's gel depot, not octreotide LAR microspheres, which do have a 14-day lag.
Option E: Option E is incorrect because oral octreotide is not the standard bridge; octreotide is a peptide degraded in the gastrointestinal tract, and continued SC octreotide is the established bridging strategy during the lag.
5. [CASE 2 — QUESTION 1]
A 44-year-old woman with acromegaly has been treated with maximum-dose lanreotide Autogel (120 mg every 28 days) for 10 months following incomplete surgical resection. Despite full adherence, her serum IGF-1 (insulin-like growth factor-1) remains 2.1 times the upper limit of normal and her GH (growth hormone) is non-suppressed. Her pituitary tumor remnant is small and does not threaten the optic chiasm. Her fasting glucose and HbA1c (hemoglobin A1c) are normal. Which change in medical therapy is most appropriate for her refractory disease?
A) Continue the same lanreotide dose unchanged, since first-generation agents eventually achieve control with longer exposure
B) Discontinue all medical therapy and observe, since SSA (somatostatin receptor analog) failure indicates no further medical option exists
C) Switch to octreotide LAR (long-acting release), because it acts at entirely different receptors than lanreotide and will succeed where lanreotide failed
D) Add sermorelin to stimulate the axis and overcome the apparent resistance
E) Switch to pasireotide LAR (long-acting release), a pan-somatostatin receptor (pan-SSTR) agonist whose high SSTR5 (somatostatin receptor subtype 5) affinity provides GH and IGF-1 suppression beyond SSTR2-selective agents and can achieve biochemical control in a portion of patients refractory to first-generation SSAs
ANSWER: E
Rationale:
This patient has acromegaly refractory to a maximally dosed first-generation, SSTR2-selective SSA, with normal glucose and no mass-effect concern. The appropriate next step is pasireotide LAR (long-acting release), a pan-somatostatin receptor (pan-SSTR) agonist whose high SSTR5 (somatostatin receptor subtype 5) affinity — roughly 40-fold greater than octreotide — provides additional GH and IGF-1 suppression and can achieve control in a portion of patients not controlled by first-generation agents. Her normal glucose makes pasireotide's principal drawback (hyperglycemia) an acceptable, monitorable risk.
Option A: Option A is incorrect because 10 months of maximum-dose lanreotide with persistent biochemical activity defines treatment failure; simply continuing the same therapy is unlikely to achieve control.
Option B: Option B is incorrect because failure of a first-generation agent does not exhaust medical options; pasireotide's broader receptor profile (or pegvisomant) remains available.
Option C: Option C is incorrect because octreotide and lanreotide are both first-generation SSTR2/SSTR5 agents with very similar receptor profiles; switching between them rarely overcomes true resistance, and the claim of entirely different receptors is false.
Option D: Option D is incorrect because sermorelin stimulates GH release and would worsen acromegaly; it has no role in treating GH excess.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. She is switched to pasireotide LAR (long-acting release). Before starting, the endocrinologist counsels her that pasireotide carries a substantially higher risk of hyperglycemia than her previous agent and explains the receptor basis for this difference. Which statement correctly describes the mechanism of pasireotide-induced hyperglycemia?
A) Pasireotide induces severe insulin resistance at the liver and skeletal muscle through interference with insulin receptor signaling, while insulin secretion remains fully intact
B) Pasireotide's high SSTR5 (somatostatin receptor subtype 5) affinity profoundly suppresses both insulin secretion from pancreatic beta cells and incretin hormone release (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) from intestinal cells, with reduced insulin secretion the dominant defect
C) Pasireotide causes hyperglycemia by stimulating glucagon secretion while leaving insulin secretion unchanged
D) Pasireotide produces hyperglycemia only by reducing renal glucose excretion, raising plasma glucose without affecting pancreatic hormone secretion
E) Pasireotide causes hyperglycemia identical in mechanism and magnitude to octreotide, through equal SSTR2 (somatostatin receptor subtype 2) effects on beta cells
ANSWER: B
Rationale:
Pasireotide's high affinity for SSTR5 (somatostatin receptor subtype 5) — roughly 40-fold greater than octreotide — profoundly suppresses insulin secretion from pancreatic beta cells and incretin hormone release (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) from intestinal cells. The dominant defect is reduced insulin secretion rather than increased insulin resistance. This is why hyperglycemia occurs in roughly 57 to 73% of pasireotide-treated patients, far more than the 10 to 20% seen with SSTR2-selective agents.
Option A: Option A is incorrect because pasireotide hyperglycemia is predominantly a secretory defect (reduced insulin secretion), not primarily insulin resistance with intact secretion.
Option C: Option C is incorrect because pasireotide suppresses both insulin and glucagon; it does not stimulate glucagon, and insulin secretion is reduced rather than unchanged.
Option D: Option D is incorrect because the mechanism is suppression of insulin and incretin secretion, not reduced renal glucose excretion.
Option E: Option E is incorrect because pasireotide's hyperglycemia is more frequent and severe than octreotide's, driven by its distinctive high SSTR5 activity rather than equal SSTR2 effects.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. Eight weeks after starting pasireotide LAR (long-acting release), her fasting glucose has risen to 196 mg/dL and her HbA1c (hemoglobin A1c) is now 8.1%. The endocrinologist must select antidiabetic therapy that fits the underlying mechanism of pasireotide hyperglycemia. Which strategy is most likely to be effective?
A) Start a GLP-1 (glucagon-like peptide-1) receptor agonist or insulin, because pasireotide suppresses endogenous insulin and incretin secretion at the source, and agents that bypass that suppression (a GLP-1 receptor agonist acting directly on its receptor, or exogenous insulin) restore effective insulin action
B) Start a DPP-4 (dipeptidyl peptidase-4) inhibitor as the preferred first agent, since it amplifies the patient's elevated endogenous incretin levels
C) Start metformin monotherapy and expect full correction, since pasireotide hyperglycemia is purely an insulin-resistance phenomenon
D) Start an SGLT2 (sodium-glucose cotransporter-2) inhibitor as monotherapy, expecting it to fully restore euglycemia by addressing the secretory defect
E) Provide no pharmacologic treatment, since pasireotide hyperglycemia always resolves spontaneously without intervention
ANSWER: A
Rationale:
Pasireotide hyperglycemia results chiefly from suppression of endogenous insulin and incretin (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) secretion at the source via high-affinity SSTR5 activity. The effective strategy bypasses the suppressed pathway: a GLP-1 receptor agonist acts directly on the GLP-1 receptor, and insulin directly replaces the suppressed secretory drive. These are the preferred agents.
Option B: Option B is incorrect because DPP-4 inhibitors work by preventing degradation of endogenous incretins; since pasireotide suppresses incretin secretion upstream, there is little substrate to preserve, making them largely ineffective.
Option C: Option C is incorrect because pasireotide hyperglycemia is predominantly a secretory defect rather than insulin resistance, so metformin alone does not address the core mechanism.
Option D: Option D is incorrect because SGLT2 inhibitors reduce renal glucose reabsorption but do not restore the suppressed insulin secretory drive, so monotherapy is insufficient.
Option E: Option E is incorrect because pasireotide hyperglycemia does not reliably resolve spontaneously while the drug is continued; it requires active management, often for the duration of therapy.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. Her glucose is brought under control with a GLP-1 (glucagon-like peptide-1) receptor agonist, and she remains on pasireotide LAR (long-acting release). The endocrinologist establishes an ongoing monitoring plan. Which combination of monitoring parameters is most appropriate for this patient on pasireotide therapy?
A) Serum GH (growth hormone) alone, since it is the only reliable marker of pasireotide efficacy and glucose need not be monitored
B) Serum prolactin and serum cortisol only, with no glucose or IGF-1 (insulin-like growth factor-1) monitoring
C) Serum IGF-1 (insulin-like growth factor-1) to assess biochemical control of acromegaly, together with fasting glucose and HbA1c (hemoglobin A1c) to monitor for pasireotide-induced hyperglycemia
D) Liver function tests every 2 weeks as the sole monitoring parameter, since hepatotoxicity is pasireotide's principal risk
E) No laboratory monitoring is required once glucose is controlled; clinical symptoms alone guide therapy
ANSWER: C
Rationale:
A patient on pasireotide for acromegaly requires monitoring of both efficacy and its characteristic toxicity. Serum IGF-1 (insulin-like growth factor-1) is the marker used to assess biochemical control of acromegaly (along with GH targets), and fasting glucose and HbA1c (hemoglobin A1c) must be followed because hyperglycemia is the principal and frequent adverse effect of pasireotide. Together these parameters capture treatment response and the most important safety concern.
Option A: Option A is incorrect because glucose monitoring is essential with pasireotide given its high hyperglycemia risk; relying on GH alone neglects both the IGF-1 efficacy marker and the dominant safety concern.
Option B: Option B is incorrect because prolactin and cortisol are not the relevant efficacy or safety markers here; IGF-1 and glucose are.
Option D: Option D is incorrect because hepatotoxicity with intensive liver monitoring is the signature of pegvisomant, not pasireotide; pasireotide's dominant concern is hyperglycemia.
Option E: Option E is incorrect because objective laboratory monitoring of IGF-1 and glucose is required; symptoms alone are insufficient to guide acromegaly therapy and detect treatment-emergent hyperglycemia.
9. [CASE 3 — QUESTION 1]
A 39-year-old man with acromegaly has been intolerant of somatostatin receptor analogs (SSAs) owing to severe gastrointestinal side effects and symptomatic cholelithiasis, and his IGF-1 (insulin-like growth factor-1) remains markedly elevated. His endocrinologist elects to start pegvisomant. To counsel the patient, the endocrinologist explains how pegvisomant differs mechanistically from the SSAs he could not tolerate. Which statement correctly describes pegvisomant's mechanism of action?
A) Pegvisomant is a somatostatin receptor analog that suppresses pituitary GH (growth hormone) secretion through SSTR2 (somatostatin receptor subtype 2) agonism, identical in mechanism to octreotide
C) Pegvisomant binds circulating IGF-1 (insulin-like growth factor-1) directly, neutralizing it before it can reach peripheral target tissues
D) Pegvisomant is a genetically engineered GH (growth hormone) receptor antagonist that binds the GH receptor (GHR) with high affinity but prevents productive receptor dimerization and JAK2-STAT5 (Janus kinase 2-signal transducer and activator of transcription 5) signaling, blocking GH action at peripheral target tissues without suppressing pituitary GH secretion
E) Pegvisomant is an oral ghrelin receptor (GHSR-1a) agonist that downregulates GH secretion through receptor desensitization
ANSWER: D
Rationale:
Pegvisomant is a genetically engineered GH (growth hormone) receptor antagonist derived from native GH with amino acid substitutions that preserve high-affinity binding to the GH receptor (GHR) but prevent productive receptor dimerization and the resulting JAK2-STAT5 (Janus kinase 2-signal transducer and activator of transcription 5) signaling. It blocks GH action at peripheral target tissues (notably the liver, reducing IGF-1 generation) without suppressing pituitary GH secretion. This peripheral receptor-blocking mechanism is fundamentally different from the SSAs the patient could not tolerate.
Option A: Option A is incorrect because pegvisomant is not a somatostatin receptor analog and does not act through SSTR2 agonism at the pituitary; that describes octreotide, not pegvisomant.
Option B: Option B is incorrect because pegvisomant does not stimulate hypothalamic somatostatin release; it acts as a peripheral GH receptor antagonist.
Option C: Option C is incorrect because pegvisomant blocks the GH receptor at target tissues rather than binding circulating IGF-1; it reduces IGF-1 by preventing its generation, not by neutralizing it directly.
Option E: Option E is incorrect because pegvisomant is an injectable GH receptor antagonist, not an oral ghrelin receptor agonist; the ghrelin receptor agonist is macimorelin, which stimulates rather than blocks the GH axis.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. After 3 months on pegvisomant, he feels substantially better. Laboratory testing shows a serum GH (growth hormone) that has risen to 26 ng/mL while his serum IGF-1 (insulin-like growth factor-1) has fallen into the normal age- and sex-adjusted range. Which laboratory parameter should be used to monitor his response to pegvisomant, and how should these results be interpreted?
A) Serum IGF-1 (insulin-like growth factor-1) is the sole reliable monitoring marker; the normal IGF-1 indicates adequate biochemical control, and the elevated GH is expected because pegvisomant does not suppress pituitary GH secretion and the fall in IGF-1 removes negative feedback, disinhibiting GH release
B) Serum GH is the correct monitoring marker; the elevated GH indicates treatment failure and the drug should be stopped
C) Both GH and IGF-1 should fall in parallel on effective therapy; their divergence indicates laboratory error requiring repeat testing
D) Serum prolactin is the preferred monitoring marker during pegvisomant therapy
E) No biochemical marker is informative during pegvisomant therapy; only tumor size on imaging guides treatment
ANSWER: A
Rationale:
During pegvisomant therapy, serum IGF-1 (insulin-like growth factor-1) is the sole reliable monitoring marker. Pegvisomant blocks the peripheral GH receptor and lowers IGF-1, but it does not suppress pituitary GH secretion; because the fall in IGF-1 removes negative feedback on the somatotroph, serum GH rises during therapy. Therefore a normal IGF-1 with an elevated GH indicates adequate biochemical control, exactly as seen here.
Option B: Option B is incorrect because the elevated GH is the expected, mechanistically predicted consequence of pegvisomant therapy and does not indicate failure; IGF-1 is the marker of success.
Option C: Option C is incorrect because GH and IGF-1 are expected to diverge during pegvisomant therapy (IGF-1 falls while GH rises); this dissociation is the predicted pharmacologic pattern, not a laboratory error.
Option D: Option D is incorrect because serum prolactin is not the monitoring marker for pegvisomant; IGF-1 is.
Option E: Option E is incorrect because IGF-1 is an essential and informative biochemical marker during pegvisomant therapy; while periodic imaging is performed because pegvisomant does not shrink tumor, biochemical response is monitored with IGF-1.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. At his 6-month visit he is asymptomatic, but surveillance liver function tests show ALT (alanine aminotransferase) at 6.1 times the upper limit of normal (ULN) and AST (aspartate aminotransferase) at 5.7 times ULN, with normal bilirubin. What is the most appropriate management based on the pegvisomant hepatotoxicity monitoring protocol?
A) Continue pegvisomant unchanged and repeat liver enzymes in 6 months, since he is asymptomatic
B) Continue pegvisomant and reduce the dose by half, rechecking enzymes in 3 months
C) Continue pegvisomant and attribute the enzyme rise to resolving acromegaly-related hepatic steatosis, requiring no change
D) Continue pegvisomant and defer any decision until enzymes exceed ten times ULN or jaundice develops
E) Discontinue pegvisomant and investigate the hepatotoxicity, because a transaminase elevation exceeding five times the upper limit of normal meets the threshold for stopping the drug regardless of symptoms
ANSWER: E
Rationale:
Hepatotoxicity is pegvisomant's principal safety concern. The monitoring protocol calls for liver function tests at baseline and periodically; an elevation exceeding three times ULN warrants more frequent monitoring, and an elevation exceeding five times the upper limit of normal (ULN) meets the threshold for discontinuing the drug pending investigation. This patient's ALT (6.1× ULN) and AST (5.7× ULN) both exceed five times ULN, so pegvisomant should be stopped and the hepatotoxicity evaluated even though he is asymptomatic with normal bilirubin.
Option A: Option A is incorrect because continuing unchanged ignores an elevation that has crossed the discontinuation threshold; absence of symptoms does not justify continuation.
Option B: Option B is incorrect because dose reduction is not the protocol response once enzymes exceed five times ULN; discontinuation is required.
Option C: Option C is incorrect because attributing a greater-than-five-times-ULN elevation to resolving steatosis would dismiss a genuine hepatotoxicity signal that must be evaluated as a possible drug effect.
Option D: Option D is incorrect because the discontinuation threshold is five times ULN, not ten; deferring until enzymes reach ten times ULN exposes the patient to avoidable risk.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. After investigation, his transaminase elevation resolves and pegvisomant is cautiously resumed at a lower dose with close monitoring, eventually re-titrated with normal liver enzymes and a normal IGF-1 (insulin-like growth factor-1). Because of a specific limitation of pegvisomant with respect to the pituitary tumor, an additional surveillance measure is required. Which surveillance is specifically indicated, and why?
A) Annual serum prolactin measurement, because pegvisomant raises prolactin and risks galactorrhea
B) Periodic (typically annual) pituitary MRI (magnetic resonance imaging), because pegvisomant blocks the GH (growth hormone) receptor only at peripheral tissues and does not reduce pituitary tumor volume, so tumor growth is not prevented and must be monitored radiologically
C) Annual bone densitometry, because pegvisomant causes accelerated bone loss requiring surveillance
D) Quarterly echocardiography, because pegvisomant is cardiotoxic and causes a dilated cardiomyopathy
E) No imaging surveillance is needed, because normalizing IGF-1 with pegvisomant reliably shrinks the pituitary tumor
ANSWER: B
Rationale:
Pegvisomant acts only at the peripheral GH (growth hormone) receptor and does not act on the pituitary tumor; consequently it does not reduce pituitary tumor volume, and tumor growth is not prevented by the drug. For this reason, periodic (typically annual) pituitary MRI (magnetic resonance imaging) is recommended during pegvisomant therapy to monitor for tumor growth, even when IGF-1 is well controlled.
Option A: Option A is incorrect because annual prolactin monitoring is not the indicated surveillance; pegvisomant does not characteristically raise prolactin or cause galactorrhea, and the relevant limitation concerns tumor volume.
Option C: Option C is incorrect because pegvisomant is not associated with accelerated bone loss requiring densitometry surveillance; the indicated surveillance is pituitary imaging.
Option D: Option D is incorrect because quarterly echocardiography for cardiotoxicity is not a pegvisomant requirement; the drug is not characterized by a dilated cardiomyopathy, and the relevant monitoring is for tumor volume.
Option E: Option E is incorrect because pegvisomant does not shrink the pituitary tumor; normalizing IGF-1 does not reduce tumor size, which is precisely why imaging surveillance is required.
13. [CASE 4 — QUESTION 1]
A 56-year-old woman who underwent resection and radiation of a non-functioning pituitary macroadenoma 2 years ago reports persistent fatigue, reduced exercise capacity, increased central adiposity, and low mood. She has a history of coronary artery disease and a remote seizure. Her endocrinologist suspects adult GH (growth hormone) deficiency and plans provocative testing to confirm it. Given her comorbidities, which diagnostic test is the most appropriate?
A) Insulin tolerance testing (ITT), because the hypoglycemia it induces is the only adequate stimulus and her cardiac and seizure history do not affect test selection
B) A random single GH (growth hormone) measurement, since a low value reliably confirms GH deficiency without provocation
C) The macimorelin stimulation test, an oral ghrelin receptor (GHSR-1a, growth hormone secretagogue receptor type 1a) agonist test that does not induce hypoglycemia and is therefore the safer choice in a patient with coronary artery disease and a seizure history, in whom insulin tolerance testing is contraindicated
D) An oral glucose tolerance test, because failure of GH to suppress establishes GH deficiency
E) A pegvisomant challenge, because blocking the GH receptor unmasks the somatotroph secretory reserve
ANSWER: C
Rationale:
The macimorelin stimulation test uses an oral ghrelin receptor (GHSR-1a, growth hormone secretagogue receptor type 1a) agonist to stimulate GH release and does not induce hypoglycemia, with a GH peak below 2.8 ng/mL establishing the diagnosis. It is the safer choice here because insulin tolerance testing (ITT) deliberately induces hypoglycemia and is contraindicated in patients with cardiovascular disease, seizure disorders, and older age — all present in this patient. Macimorelin offers sensitivity and specificity comparable to ITT.
Option A: Option A is incorrect because the patient's cardiac and seizure history are highly relevant: ITT-induced hypoglycemia is hazardous and contraindicated in these conditions, so ITT is inappropriate.
Option B: Option B is incorrect because a single random GH measurement cannot establish GH deficiency owing to pulsatile, often-low baseline GH secretion; provocative testing is required.
Option D: Option D is incorrect because the oral glucose tolerance test with GH suppression diagnoses acromegaly (GH excess), not GH deficiency.
Option E: Option E is incorrect because there is no pegvisomant challenge test for diagnosing GH deficiency; pegvisomant is a therapeutic GH receptor antagonist for acromegaly, not a diagnostic agent.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. The macimorelin test confirms adult GH (growth hormone) deficiency, and somatropin (recombinant human GH) replacement is planned. She asks why the drug must be injected daily rather than taken as a pill, given that she has read its blood half-life is only a few hours. Which explanation correctly addresses both the route of administration and the rationale for once-daily dosing?
A) Somatropin can be taken orally but is injected by patient preference; once-daily dosing reflects its 24-hour plasma half-life
B) Somatropin must be injected because it is too lipophilic to dissolve in the gut; once-daily dosing works because subcutaneous fat slowly releases the drug over 24 hours
C) Somatropin must be injected because the stomach lacks a GH-specific transporter; once-daily dosing reflects slow hepatic first-pass metabolism that prolongs its action
D) Somatropin is a 191-amino acid peptide that would be degraded by gastrointestinal proteases if taken orally, so it is given by subcutaneous (SC) injection; once-daily dosing is justified because each dose induces IGF-1 (insulin-like growth factor-1), which has a circulating half-life of approximately 12 to 15 hours and mediates the sustained biological effect well beyond somatropin's own 2 to 4-hour plasma half-life
E) Somatropin must be injected because oral absorption produces toxic peak levels; once-daily dosing is used to mimic pulsatile nocturnal GH secretion
ANSWER: D
Rationale:
Somatropin is a 191-amino acid single-chain polypeptide that, like other protein hormones, would be degraded by gastrointestinal proteases if taken orally; it is therefore administered parenterally, nearly always by subcutaneous (SC) injection. Although somatropin's own plasma half-life is short (approximately 2 to 4 hours), once-daily dosing is justified pharmacodynamically: each dose induces hepatic IGF-1 (insulin-like growth factor-1) synthesis, and circulating IGF-1 has a half-life of approximately 12 to 15 hours and mediates most of the sustained biological effects of GH, providing activity well beyond somatropin's brief presence in plasma.
Option A: Option A is incorrect because somatropin cannot be taken orally (it is degraded by proteases), and it does not have a 24-hour plasma half-life.
Option B: Option B is incorrect because the barrier to oral delivery is proteolytic degradation, not lipophilicity, and sustained effect derives from IGF-1, not slow release from subcutaneous fat.
Option C: Option C is incorrect because the issue is enzymatic degradation, not a missing transporter, and once-daily dosing is explained by IGF-1 kinetics, not prolonged first-pass metabolism.
Option E: Option E is incorrect because somatropin is not orally bioavailable at all (it is destroyed, not excessively absorbed), and once-daily dosing rests on IGF-1's half-life rather than on mimicking nocturnal pulsatility.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. Her pituitary history includes panhypopituitarism, and she is also on stable hydrocortisone and levothyroxine replacement. Several weeks after starting somatropin, she develops worsening fatigue, nausea, anorexia, and orthostatic lightheadedness, and a morning cortisol is low. Which mechanism best explains this development?
A) Somatropin directly suppresses pituitary ACTH (adrenocorticotropic hormone) secretion through IGF-1 (insulin-like growth factor-1) feedback, independent of her hydrocortisone dose
B) Somatropin induces CYP3A4 (cytochrome P450 3A4), accelerating hydrocortisone clearance; in a patient with limited adrenal reserve on a borderline replacement dose, this increased clearance lowers effective cortisol exposure and unmasks adrenal insufficiency
C) Somatropin displaces cortisol from corticosteroid-binding globulin, raising free cortisol and causing a glucocorticoid-excess state
D) Somatropin inhibits 11-beta-hydroxysteroid dehydrogenase, trapping cortisol as cortisone and causing mineralocorticoid excess
E) Somatropin causes acute hyperglycemia that precipitates these symptoms, unrelated to glucocorticoid metabolism
ANSWER: B
Rationale:
Somatropin induces CYP3A4 (cytochrome P450 3A4), accelerating the clearance of glucocorticoids such as hydrocortisone and increasing conversion of cortisol to inactive cortisone. In a patient with panhypopituitarism and limited adrenal reserve maintained on a borderline hydrocortisone dose, this increased clearance can reduce effective cortisol exposure and unmask adrenal insufficiency, presenting as fatigue, nausea, anorexia, orthostatic symptoms, and a low morning cortisol. The appropriate response is to increase the hydrocortisone dose (commonly by 20 to 30%).
Option A: Option A is incorrect because the mechanism is accelerated glucocorticoid clearance via CYP3A4 induction, not direct IGF-1-mediated ACTH suppression; this patient already has central adrenal insufficiency and is on replacement.
Option C: Option C is incorrect because somatropin does not displace cortisol from corticosteroid-binding globulin to cause excess; the clinical picture is insufficiency, and the mechanism is enzymatic clearance.
Option D: Option D is incorrect because the dominant mechanism of reduced glucocorticoid exposure here is CYP3A4 induction with accelerated hepatic clearance, not 11-beta-hydroxysteroid dehydrogenase inhibition causing mineralocorticoid excess; the presentation is glucocorticoid insufficiency, not sodium retention or mineralocorticoid excess.
Option E: Option E is incorrect because somatropin can worsen glucose tolerance over time but does not typically produce an acute hyperglycemic crisis with low cortisol; the findings indicate unmasked adrenal insufficiency from accelerated glucocorticoid clearance.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. Her hydrocortisone dose is increased and her symptoms resolve. She is also taking oral conjugated estrogen for menopausal symptoms. Despite an appropriate somatropin dose, her serum IGF-1 (insulin-like growth factor-1) remains persistently below target. Her endocrinologist considers the effect of her estrogen route on GH (growth hormone) replacement. Which statement correctly explains the interaction and its implication?
A) Oral estrogen undergoes first-pass portal delivery to the liver at high concentration, where it suppresses hepatic GH (growth hormone) receptor signaling and reduces IGF-1 (insulin-like growth factor-1) production for any given somatropin dose; women on oral estrogen therefore require higher somatropin doses, and switching to transdermal estradiol (which bypasses the portal first-pass effect) would lower the somatropin requirement
B) Oral estrogen accelerates renal clearance of IGF-1 (insulin-like growth factor-1), lowering serum levels, whereas transdermal estradiol does not
C) Oral estrogen blocks subcutaneous absorption of somatropin at the injection site, reducing systemic exposure
D) Transdermal estradiol suppresses pituitary GH (growth hormone) secretion more than oral estrogen, so the oral route is preferable for GH-deficient women
E) Estrogen route has no effect on IGF-1 (insulin-like growth factor-1); the low level reflects assay variability rather than a pharmacologic interaction
ANSWER: A
Rationale:
Oral estrogen is absorbed into the portal circulation and reaches the liver at high first-pass concentration, where it suppresses hepatic GH (growth hormone) receptor signaling and reduces IGF-1 (insulin-like growth factor-1) production in response to a given somatropin dose. Consequently, women on oral estrogen require higher somatropin doses to reach target IGF-1, and switching to transdermal estradiol — which enters the systemic circulation directly and bypasses the portal first-pass effect — reduces hepatic estrogen exposure and lowers the somatropin requirement.
Option B: Option B is incorrect because the mechanism is suppressed hepatic IGF-1 production, not accelerated renal IGF-1 clearance.
Option C: Option C is incorrect because oral estrogen does not block subcutaneous somatropin absorption; the interaction occurs at hepatic IGF-1 generation, not at the injection site.
Option D: Option D is incorrect because it inverts the relationship: oral estrogen (not transdermal) suppresses hepatic IGF-1 production and raises the somatropin requirement, and the effect is on hepatic IGF-1 generation rather than pituitary GH suppression.
Option E: Option E is incorrect because the route-dependent first-pass effect of estrogen on hepatic IGF-1 is a real, well-documented pharmacologic interaction, not assay variability.
17. [CASE 5 — QUESTION 1]
A 49-year-old man with HIV (human immunodeficiency virus) on stable antiretroviral therapy has developed disfiguring central abdominal fat accumulation with imaging confirming marked visceral adipose tissue (VAT) excess from antiretroviral therapy-associated lipodystrophy. He has no active malignancy. His clinician seeks a pharmacologic agent specifically indicated to reduce his visceral adipose tissue. Which agent is appropriate, and what is its classification?
A) Octreotide LAR (long-acting release), a somatostatin receptor analog that reduces visceral fat by suppressing GH (growth hormone)
B) Pegvisomant, a GH (growth hormone) receptor antagonist that mobilizes visceral fat by blocking GH action
C) Somatropin at high replacement doses, the approved direct-GH (growth hormone) therapy for HIV-associated lipodystrophy
D) Macimorelin, an oral diagnostic agent that also reduces central fat during stimulation testing
E) Tesamorelin, a synthetic GHRH (growth hormone-releasing hormone) analog stabilized against dipeptidyl peptidase-4 (DPP-4) cleavage that stimulates endogenous GH (growth hormone) release and is FDA (U.S. Food and Drug Administration)-approved to reduce excess visceral adipose tissue in HIV-associated lipodystrophy
ANSWER: E
Rationale:
Tesamorelin is a synthetic GHRH (growth hormone-releasing hormone) analog stabilized by an N-terminal modification that protects it from dipeptidyl peptidase-4 (DPP-4) cleavage. It stimulates endogenous GH release and is FDA (U.S. Food and Drug Administration)-approved specifically to reduce excess visceral adipose tissue (VAT) in HIV (human immunodeficiency virus)-infected patients with antiretroviral therapy-associated lipodystrophy. With no active malignancy (a contraindication), this patient is an appropriate candidate.
Option A: Option A is incorrect because octreotide is a somatostatin receptor analog used to suppress GH in conditions such as acromegaly; it is not indicated for HIV lipodystrophy.
Option B: Option B is incorrect because pegvisomant is a GH receptor antagonist for acromegaly; blocking the GH receptor would not reduce VAT in lipodystrophy.
Option C: Option C is incorrect because high-dose somatropin replacement is not the approved therapy for HIV-associated lipodystrophy VAT reduction; the approved agent is tesamorelin.
Option D: Option D is incorrect because macimorelin is a single-dose oral diagnostic agent for GH deficiency and has no therapeutic role in reducing visceral fat.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Before starting tesamorelin, the clinician explains how the drug works at the level of the pituitary and why it differs from simply giving recombinant GH (growth hormone). Which statement correctly describes tesamorelin's mechanism of action?
A) Tesamorelin replaces circulating GH (growth hormone) directly, acting as an exogenous form of the hormone independent of pituitary function
B) Tesamorelin blocks the GH (growth hormone) receptor at adipose tissue, directly preventing fat storage
C) Tesamorelin is a GHRH (growth hormone-releasing hormone) analog that binds the GHRH receptor on pituitary somatotrophs and stimulates endogenous GH release in a physiological pulsatile pattern, preserving negative feedback; because it acts upstream at the pituitary, it requires an intact somatotroph pool to be effective
D) Tesamorelin suppresses somatostatin tone at the hypothalamus, indirectly raising GH (growth hormone) by removing inhibition rather than by receptor stimulation
E) Tesamorelin is a ghrelin receptor antagonist that lowers appetite, reducing visceral fat through caloric restriction rather than through GH (growth hormone) stimulation
ANSWER: C
Rationale:
Tesamorelin is a GHRH (growth hormone-releasing hormone) analog that binds the GHRH receptor on pituitary somatotrophs and stimulates endogenous GH (growth hormone) release in a physiological pulsatile pattern, preserving the normal negative feedback relationship between GH and IGF-1 (insulin-like growth factor-1). Because it acts upstream at the pituitary rather than replacing GH directly, it requires an intact somatotroph pool to be effective.
Option A: Option A is incorrect because tesamorelin does not replace circulating GH directly; that describes somatropin. It stimulates endogenous release and depends on pituitary function.
Option B: Option B is incorrect because tesamorelin does not block the GH receptor at adipose tissue; it stimulates GH secretion at the pituitary.
Option D: Option D is incorrect because tesamorelin acts as a direct GHRH receptor agonist, not by suppressing hypothalamic somatostatin tone.
Option E: Option E is incorrect because tesamorelin is a GHRH receptor agonist, not a ghrelin receptor antagonist; it reduces visceral fat through GH stimulation, not through appetite-mediated caloric restriction.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. He tolerates tesamorelin well, with measurable reduction in trunk fat over several months. At a follow-up visit, screening reveals a newly diagnosed colorectal adenocarcinoma. What is the most appropriate action regarding tesamorelin, and what is the pharmacologic rationale?
A) Continue tesamorelin unchanged, because its visceral fat reduction benefits outweigh any oncologic concern
B) Continue tesamorelin but reduce the dose by half, because malignancy only partially contraindicates GHRH (growth hormone-releasing hormone) analog therapy
C) Continue tesamorelin and add a somatostatin receptor analog to counteract any tumor-promoting effect
D) Discontinue tesamorelin, because it stimulates endogenous GH (growth hormone) release and raises circulating IGF-1 (insulin-like growth factor-1), which has growth-promoting and anti-apoptotic effects at tumor cells; active malignancy is therefore a contraindication to tesamorelin
E) Switch tesamorelin to high-dose somatropin, since direct GH (growth hormone) replacement is safe in active malignancy
ANSWER: D
Rationale:
Tesamorelin stimulates endogenous GH (growth hormone) release, which raises circulating IGF-1 (insulin-like growth factor-1). IGF-1 has well-established growth-promoting and anti-apoptotic effects at the cellular level, including actions on tumor cells, so active malignancy is a contraindication to tesamorelin. With a newly diagnosed colorectal adenocarcinoma, tesamorelin should be discontinued.
Option A: Option A is incorrect because the oncologic concern of raising IGF-1 in active malignancy outweighs the cosmetic and metabolic benefit; continuation is contraindicated.
Option B: Option B is incorrect because active malignancy is a contraindication, not a dose-reduction indication; the drug should be stopped, not merely reduced.
Option C: Option C is incorrect because adding a somatostatin receptor analog is not the appropriate management; the correct action is discontinuation of tesamorelin.
Option E: Option E is incorrect because somatropin shares the same IGF-1-raising oncologic concern and is likewise contraindicated in active malignancy; switching to high-dose GH would not be safe.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. Consider instead a counterfactual in which he had no malignancy and remained on tesamorelin. He has baseline insulin resistance with impaired fasting glucose. Which metabolic adverse effect should be monitored during tesamorelin therapy, and why?
A) Hypoglycemia, because tesamorelin enhances insulin secretion and predisposes to low glucose
B) Worsening glucose tolerance, because tesamorelin stimulates endogenous GH (growth hormone) release and GH is a counter-regulatory hormone that reduces insulin sensitivity; the accompanying rise in IGF-1 (insulin-like growth factor-1) and GH effects can worsen glycemia in a patient with pre-existing insulin resistance, so glucose should be monitored
C) Severe hypokalemia, because tesamorelin causes a mineralocorticoid-like renal potassium wasting effect
D) Profound hyponatremia from tesamorelin-induced syndrome of inappropriate antidiuresis
E) No metabolic monitoring is required, because tesamorelin has no effect on glucose metabolism
ANSWER: B
Rationale:
Tesamorelin stimulates endogenous GH (growth hormone) release, and GH is a counter-regulatory hormone that reduces insulin sensitivity and promotes hepatic glucose output. In a patient with pre-existing insulin resistance and impaired fasting glucose, the rise in GH and IGF-1 (insulin-like growth factor-1) with tesamorelin can worsen glucose tolerance, so glucose should be monitored during therapy.
Option A: Option A is incorrect because tesamorelin does not enhance insulin secretion or predispose to hypoglycemia; the relevant risk is worsening hyperglycemia through GH's counter-regulatory effect.
Option C: Option C is incorrect because tesamorelin does not cause mineralocorticoid-like renal potassium wasting or hypokalemia.
Option D: Option D is incorrect because tesamorelin is not associated with syndrome of inappropriate antidiuresis or profound hyponatremia.
Option E: Option E is incorrect because tesamorelin does affect glucose metabolism — it can worsen glycemia via GH's counter-regulatory action — so metabolic monitoring is warranted, especially in an insulin-resistant patient.
21. [CASE 6 — QUESTION 1]
A 58-year-old man with acromegaly, type 2 diabetes mellitus, and a prior kidney transplant maintained on cyclosporine is started on octreotide LAR (long-acting release) for residual GH (growth hormone) excess after surgery. At initiation, his endocrinologist warns that the effect of the somatostatin receptor analog (SSA) on his glycemic control cannot be predicted in advance. Which mechanism best explains this unpredictability?
A) SSAs suppress both insulin and glucagon secretion from pancreatic islets; because insulin lowers glucose and glucagon raises it, the net glycemic effect depends on which suppression predominates in a given patient, so the direction of glucose change is unpredictable and early glucose monitoring is required
B) SSAs reliably raise insulin secretion and lower glucagon, so glucose always falls and only hypoglycemia need be anticipated
C) SSAs have no effect on islet hormones, so any glucose change after initiation is coincidental
D) SSAs selectively destroy pancreatic alpha cells, guaranteeing severe hyperglycemia in every patient
E) SSAs increase incretin secretion, reliably improving glucose tolerance and making the warning unnecessary
ANSWER: A
Rationale:
Somatostatin receptor analogs (SSAs) suppress secretion of both insulin and glucagon from pancreatic islets. Because insulin lowers blood glucose and glucagon raises it, suppressing both produces opposing influences on glycemia; the net effect in any individual depends on which suppression predominates. As a result, the direction of glucose change after starting an SSA is not predictable, and glucose should be monitored closely in the early weeks, particularly in a diabetic patient.
Option B: Option B is incorrect because SSAs suppress (not raise) insulin secretion, so glucose does not always fall; the premise is wrong.
Option C: Option C is incorrect because SSAs have well-defined effects on islet hormones; the glycemic variability is drug-related, not coincidental.
Option D: Option D is incorrect because SSAs functionally suppress islet hormone secretion rather than destroying alpha cells, and the effect is not uniformly severe hyperglycemia in every patient.
Option E: Option E is incorrect because first-generation SSAs do not reliably increase incretin secretion or improve glucose tolerance; the unpredictable bidirectional islet effect is exactly why monitoring is warranted.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. Because he is a kidney transplant recipient on cyclosporine, the endocrinologist is concerned about a drug interaction with the newly started octreotide. Which monitoring action is most important to prevent a serious complication of this combination?
A) Monitor for cyclosporine toxicity from elevated levels, because octreotide inhibits CYP3A4 (cytochrome P450 3A4) and raises cyclosporine concentrations
B) No monitoring is needed, because octreotide and cyclosporine do not interact
C) Monitor serum magnesium only, because the interaction is limited to renal electrolyte wasting
D) Preemptively reduce the cyclosporine dose, because octreotide predictably doubles cyclosporine plasma levels
E) Monitor cyclosporine trough levels, because somatostatin receptor analogs reduce gastrointestinal absorption of cyclosporine, which can lower its plasma concentrations and precipitate acute allograft rejection; the dose may need to be increased
ANSWER: E
Rationale:
Somatostatin receptor analogs (SSAs) such as octreotide reduce the gastrointestinal absorption of cyclosporine by inhibiting intestinal motility and secretion. Because cyclosporine already has variable and relatively low oral bioavailability, this reduced absorption can meaningfully lower plasma trough concentrations. In a transplant recipient, subtherapeutic cyclosporine raises the risk of acute allograft rejection, a serious complication. The most important monitoring action is therefore to follow cyclosporine trough levels after starting the SSA, increasing the dose if needed.
Option A: Option A is incorrect because octreotide does not inhibit CYP3A4 or raise cyclosporine levels; the interaction reduces cyclosporine absorption and lowers levels, the opposite direction.
Option B: Option B is incorrect because there is a clinically important interaction; ignoring it could lead to rejection.
Option C: Option C is incorrect because the principal concern is reduced cyclosporine absorption and rejection risk, not isolated magnesium wasting.
Option D: Option D is incorrect because octreotide lowers rather than raises cyclosporine levels, so preemptive dose reduction would be the wrong action and could precipitate rejection.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. After about 18 months of octreotide LAR (long-acting release), he develops intermittent right upper quadrant pain after meals, and ultrasound reveals new gallstones in a previously normal gallbladder. What is the most likely mechanism of this complication?
A) Octreotide increases hepatic cholesterol synthesis through CYP7A1 (cytochrome P450 7A1) induction, the dominant mechanism of stone formation
B) Octreotide accelerates gallbladder emptying so forcefully that bile crystallizes in the cystic duct
C) Octreotide suppresses cholecystokinin (CCK) release and inhibits gallbladder contractility, producing bile stasis that promotes cholesterol gallstone formation; this occurs in roughly 20 to 30% of patients on long-term somatostatin receptor analog therapy
D) Octreotide precipitates calcium bilirubinate stones through an osmotic effect limited to patients with pre-existing biliary disease
E) The gallstones are unrelated to octreotide and reflect only his dietary fat intake
ANSWER: C
Rationale:
Somatostatin receptor analogs, including octreotide, suppress cholecystokinin (CCK) release and inhibit gallbladder contractility. CCK normally drives postprandial gallbladder emptying; with its suppression, bile stagnates, becomes supersaturated with cholesterol, and forms gallstones. Symptomatic gallstones develop in roughly 20 to 30% of patients on long-term SSA therapy, consistent with this patient's 18-month course, postprandial right upper quadrant pain, and new stones in a previously normal gallbladder.
Option A: Option A is incorrect because octreotide does not cause stones by CYP7A1 induction or increased hepatic cholesterol synthesis; the mechanism is reduced gallbladder motility from CCK suppression.
Option B: Option B is incorrect because octreotide reduces, not accelerates, gallbladder contractility; the pathophysiology is stasis from impaired emptying.
Option D: Option D is incorrect because SSA-associated cholelithiasis is not an osmotic calcium bilirubinate process limited to pre-existing biliary disease; it arises in previously normal gallbladders through bile stasis and cholesterol supersaturation.
Option E: Option E is incorrect because the stones are very plausibly related to long-term octreotide; attributing them solely to dietary fat ignores a well-established class effect occurring in 20 to 30% of treated patients.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. His cholelithiasis is managed conservatively and octreotide is continued, but his IGF-1 (insulin-like growth factor-1) remains above target despite the maximum SSA (somatostatin receptor analog) dose, and a small tumor remnant persists. The endocrinologist adds pegvisomant to the SSA rather than switching to pegvisomant alone. What is the rationale for combination therapy?
A) Combining the two agents merely reduces drug cost, with no pharmacologic rationale
B) The two agents act at the same pituitary receptor, producing simple additive occupancy and nothing more
C) Pegvisomant shrinks the tumor while the SSA normalizes IGF-1 (insulin-like growth factor-1), each covering the other in the opposite direction from their true effects
D) The SSA acts at the pituitary somatotroph to suppress GH (growth hormone) secretion and restrain tumor growth, while pegvisomant blocks the GH (growth hormone) receptor peripherally to drive IGF-1 (insulin-like growth factor-1) into the normal range; combining them achieves superior biochemical control while retaining the SSA's restraint on the tumor remnant, which pegvisomant alone does not provide
E) Pegvisomant stimulates the GH (growth hormone) axis and the SSA suppresses it, so the two cancel out and stabilize the patient at baseline
ANSWER: D
Rationale:
The rationale for combining a somatostatin receptor analog (SSA) with pegvisomant rests on their complementary sites of action. The SSA acts at the pituitary somatotroph, suppressing GH (growth hormone) secretion and offering restraint on tumor growth, while pegvisomant acts peripherally at the GH receptor to block IGF-1 (insulin-like growth factor-1) generation and is highly effective at normalizing IGF-1. Adding pegvisomant to a maximally dosed SSA — rather than switching — achieves superior biochemical control of IGF-1 while retaining the SSA's restraining effect on the tumor remnant, which pegvisomant monotherapy (with no tumor-volume effect) does not provide.
Option A: Option A is incorrect because the rationale is pharmacologic (complementary mechanisms), not cost; combination therapy is generally more expensive.
Option B: Option B is incorrect because the agents act at different receptors — pituitary somatostatin receptors versus peripheral GH receptors — so the benefit is complementary, not same-receptor additivity.
Option C: Option C is incorrect because it inverts the true effects: pegvisomant does not shrink tumor, and the SSA is not the primary IGF-1 normalizer in refractory disease; each contributes its actual effect (SSA = tumor restraint/GH suppression; pegvisomant = IGF-1 normalization).
Option E: Option E is incorrect because pegvisomant antagonizes the peripheral GH receptor rather than stimulating the axis, so the agents do not simply cancel out.
25. [CASE 7 — QUESTION 1]
A 60-year-old man with adult GH (growth hormone) deficiency from prior pituitary surgery has been on stable somatropin (recombinant GH) replacement for 4 years with good biochemical control. He is admitted to the intensive care unit with necrotizing pancreatitis complicated by septic shock and acute respiratory failure requiring mechanical ventilation. The ICU team asks how to manage his somatropin during this critical illness. What is the most appropriate action?
A) Continue somatropin at his usual dose, because years of tolerance mean it poses no new risk during acute illness
B) Discontinue somatropin for the duration of the acute critical illness, because acute critical illness is a contraindication to somatropin — pharmacological GH (growth hormone) exposure increased mortality in critically ill patients in pivotal trials — and restart it after recovery
C) Increase the somatropin dose to provide anabolic support and accelerate recovery
D) Continue somatropin but switch to a once-weekly long-acting formulation for ICU convenience
E) Continue somatropin and add a somatostatin receptor analog to offset any excess GH (growth hormone) effect during the illness
ANSWER: B
Rationale:
Acute critical illness is a contraindication to somatropin, independent of prior tolerance, because pivotal controlled trials demonstrated increased mortality when critically ill adults received GH (growth hormone). The contraindication is tied to the patient's current physiologic state, so a patient established on replacement who becomes critically ill should have somatropin discontinued for the duration of the acute illness and restarted after recovery.
Option A: Option A is incorrect because prior long-term tolerance does not exempt the patient from a state-dependent contraindication; the risk arises from the acute critical illness itself.
Option C: Option C is incorrect because increasing the dose is the opposite of correct management; pharmacological GH exposure increased mortality in critically ill patients, so escalation is hazardous.
Option D: Option D is incorrect because switching formulations does not address the contraindication; somatropin should be held, not merely rescheduled.
Option E: Option E is incorrect because adding a somatostatin receptor analog is not the appropriate strategy; the correct action is to discontinue somatropin during the critical illness.
26. [CASE 7 — QUESTION 2]
Continuing with the same patient. Somatropin is discontinued for the critical illness. He also has coexisting central adrenal insufficiency and is maintained on hydrocortisone replacement, a dose that had been titrated upward while he was taking somatropin. As he recovers and somatropin remains held, which consideration regarding his glucocorticoid replacement is correct?
A) Stopping somatropin reverses its CYP3A4 (cytochrome P450 3A4) induction, slowing hydrocortisone clearance; a hydrocortisone dose that was titrated upward to offset somatropin-accelerated clearance may now be relatively excessive, so the glucocorticoid dose should be reassessed and likely reduced
B) Stopping somatropin further accelerates hydrocortisone clearance, so the hydrocortisone dose must be increased
C) Stopping somatropin has no effect on hydrocortisone metabolism, so the glucocorticoid dose never requires reassessment
D) Stopping somatropin permanently destroys CYP3A4 (cytochrome P450 3A4), so hydrocortisone should be discontinued entirely
E) Stopping somatropin converts hydrocortisone into an active mineralocorticoid, requiring addition of spironolactone
ANSWER: A
Rationale:
Somatropin induces CYP3A4 (cytochrome P450 3A4) and accelerates glucocorticoid clearance; a hydrocortisone dose titrated upward during somatropin therapy was set against that accelerated clearance. When somatropin is discontinued, the CYP3A4 induction reverses and hydrocortisone clearance slows, so the previously increased dose may now be relatively excessive. The glucocorticoid replacement should therefore be reassessed and likely reduced to avoid overexposure.
Option B: Option B is incorrect because stopping somatropin slows, rather than further accelerates, hydrocortisone clearance (induction is removed), so the dose would not need to be increased on this basis.
Option C: Option C is incorrect because the somatropin-glucocorticoid interaction is bidirectional and clinically relevant; stopping the inducer does change hydrocortisone exposure and warrants reassessment.
Option D: Option D is incorrect because CYP3A4 induction is reversible, not a permanent destruction of the enzyme, and a patient with central adrenal insufficiency still requires glucocorticoid replacement — it should not be discontinued.
Option E: Option E is incorrect because somatropin does not convert hydrocortisone into a mineralocorticoid; the interaction is enzymatic clearance, and spironolactone is not indicated.
27. [CASE 7 — QUESTION 3]
Continuing with the same patient. After recovery, his team reviews his GH (growth hormone) deficiency. His prior pituitary surgery and postoperative radiation are documented to have destroyed the somatotroph population. A trainee asks whether a GHRH (growth hormone-releasing hormone) analog such as sermorelin could be used instead of somatropin to stimulate his own GH (growth hormone) production. What is the correct answer, and why?
A) Yes; a GHRH (growth hormone-releasing hormone) analog will work because it replaces circulating GH (growth hormone) directly regardless of pituitary status
B) Yes; radiation sensitizes the remaining pituitary tissue, enhancing the response to a GHRH (growth hormone-releasing hormone) analog
C) Yes; a GHRH (growth hormone-releasing hormone) analog bypasses the pituitary entirely and acts at peripheral tissues to raise IGF-1 (insulin-like growth factor-1)
D) No; GHRH (growth hormone-releasing hormone) analogs are contraindicated only because they cause hypoglycemia, not because of any pituitary requirement
E) No; GHRH (growth hormone-releasing hormone) analogs act upstream at the pituitary and require a functioning somatotroph pool to stimulate endogenous GH (growth hormone) release, so they are ineffective when the somatotrophs have been destroyed by radiation; this patient requires direct GH (growth hormone) replacement with somatropin
ANSWER: E
Rationale:
GHRH (growth hormone-releasing hormone) analogs such as sermorelin act upstream at the pituitary, stimulating somatotrophs to release endogenous GH (growth hormone); they do not replace GH directly. Their efficacy therefore depends on an intact somatotroph pool. In this patient, prior surgery and radiation destroyed the somatotroph population, so a GHRH analog would have no functional target cells to stimulate and would be ineffective. He requires direct GH replacement with somatropin.
Option A: Option A is incorrect because GHRH analogs do not replace circulating GH directly; that is somatropin's role, and GHRH analogs depend on pituitary function.
Option B: Option B is incorrect because radiation destroys rather than sensitizes the somatotrophs; it removes the target cells the analog would need.
Option C: Option C is incorrect because GHRH analogs act at the pituitary GHRH receptor, not at peripheral tissues, and they cannot bypass an absent somatotroph population to raise IGF-1.
Option D: Option D is incorrect because GHRH analogs do not cause hypoglycemia, and the reason they fail here is the absence of functioning somatotrophs, not a hypoglycemia-related contraindication.
28. [CASE 7 — QUESTION 4]
Continuing with the same patient. To consolidate the teaching point, the attending asks the trainee to summarize the fundamental pharmacologic distinction between sermorelin and somatropin. Which statement correctly contrasts the two agents?
A) Both sermorelin and somatropin are recombinant forms of growth hormone (GH) that replace the hormone directly, differing only in their dosing intervals
B) Both sermorelin and somatropin are GHRH (growth hormone-releasing hormone) analogs that stimulate the pituitary, differing only in receptor affinity
C) Sermorelin is a GHRH (growth hormone-releasing hormone) analog that stimulates the pituitary somatotroph to release endogenous GH (growth hormone) and therefore requires an intact somatotroph pool, whereas somatropin is recombinant human GH (growth hormone) that replaces the hormone directly and works independently of pituitary function
D) Sermorelin directly replaces circulating GH (growth hormone), whereas somatropin stimulates the pituitary to release endogenous GH (growth hormone)
E) Sermorelin is a growth hormone (GH) receptor antagonist and somatropin is a somatostatin receptor analog, so the two have opposing effects on IGF-1 (insulin-like growth factor-1)
ANSWER: C
Rationale:
Sermorelin and somatropin act at fundamentally different points in the GH (growth hormone) axis. Sermorelin is a GHRH (growth hormone-releasing hormone) analog (the active N-terminal 1-29 fragment of GHRH) that stimulates the pituitary somatotroph to release endogenous GH; because it acts upstream at the pituitary, it requires an intact somatotroph pool to be effective. Somatropin is recombinant human GH that replaces the hormone directly at the periphery and therefore works regardless of pituitary somatotroph function, making it the appropriate choice when somatotrophs are absent.
Option A: Option A is incorrect because sermorelin is not a recombinant form of GH; it is a GHRH analog that stimulates endogenous release rather than replacing the hormone.
Option B: Option B is incorrect because somatropin is not a GHRH analog; it is recombinant GH, so the two do not share a stimulate-the-pituitary mechanism.
Option D: Option D is incorrect because it inverts the two agents: sermorelin stimulates the pituitary to release endogenous GH, whereas somatropin replaces circulating GH directly.
Option E: Option E is incorrect because sermorelin is not a GH receptor antagonist (that is pegvisomant) and somatropin is not a somatostatin receptor analog (that is octreotide); both sermorelin and somatropin ultimately raise GH activity rather than having opposing effects on IGF-1.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.